The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Wong, C ^a   Laddha, S V ^b   Tang, L ^c   Vosburgh, E ^a,b   Levine, A J ^b,d   Normant, E ^e   Sandy, P ^e   Harris, C R ^a,b   Chan, C S ^b   Xu, E Y ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d INSTITUTE FOR ADVANCED STUDY   (United States)

^e Department of Structural Biology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROMODOMAIN INHIBITOR; CPI 203; MYC PROTEIN; PROTEIN KINASE B; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ACETAMIDE DERIVATIVE; AZEPINE DERIVATIVE; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; CPI203; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOLAYER CULTURE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PHENOTYPE; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR SPHEROID; TUMOR XENOGRAFT; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; GENETICS; METABOLISM; NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY;

ACETAMIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZEPINES; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; RNA-BINDING PROTEINS; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 84928011407     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.396     Document Type: Article

References (43)

1. Liu E, Marincola P, Oberg K. Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations. Therap Adv Gastroenterol 2013; 6: 412-419.
2. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318.
3. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 2011; 364: 501-513.
4. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch DWinkler RE et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
5. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011; 364: 514-523.
6. Levens D. Disentangling the MYC web. Proc Natl Acad Sci USA 2002; 99: 5757-5759.
7. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011; 25: 907-916.
8. Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med 2011; 13: e29.
9. Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J 2000; 19: 6141-6149.
10. Miyoshi SOS, Iwata K, Hikawa HSugaraha K Antitumor Agent. International Patent No PCT/JP2008/073864 (WO/2009/084693) 2009.
11. Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxyterminal domain. Proc Natl Acad Sci USA 2012; 109: 6927-6932.
12. King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell 2013;153: 1552-1566.
13. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O et al. Selective inhibition of BET bromodomains. Nature 2010; 468: 1067-1073.
14. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478:524-528.
15. Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res 2013; 73: 3336-3346.
16. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011;108: 16669-16674.
17. Ruggero D. The role of Myc-induced protein synthesis in cancer. Cancer Res 2009; 69: 8839-8843.
18. Zou Z, Huang B, Wu X, Zhang H, Qi JBradner J et al. Brd4 maintains constitutively active NF-kappaB in cancer cells by binding to acetylated RelA. Oncogene 2013; 33:2395-2404.
19. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34: 267-273.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
21. Bild AH, Yao G, Chang JT, Wang Q, Potti AChasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
22. Lebwohl D, Anak O, Sahmoud T, Klimovsky J, Elmroth I, Haas T et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann NY Acad Sci 2013; 1291: 14-32.
23. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F et al. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res 2012; 18: 1777-1789.
24. O'Reilly KE, Rojo F, She QB, Solit D, Mills GBSmith D et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-1508.
25. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
26. Chou TCMartin N CompuSyn for Drug Combinations: PC Software and User's Guide: a Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 Values, ComboSyn Inc, Paramus, (NJ) 2005.
27. Wall M, Poortinga G, Hannan KM, Pearson RB, Hannan RDMcArthur GA. Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood 2008; 112: 2305-2317.
28. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA. Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010; 148: 3-15.
29. Wong C, Vosburgh E, Levine AJ, Cong L, Xu EY. Human neuroendocrine tumor cell lines as a three-dimensional model for the study of human neuroendocrine tumor therapy. J Vis Exp 2012; 66: e4218.
30. Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput image analysis of tumor spheroids: a user-friendly software application to measure the size of spheroids automatically and accurately. J Vis Exp 2014; 89
31. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
32. Pavelic K, Hrascan R, Kapitanovic S, Karapandza N, Vranes Z, Belicza M et al. Multiple genetic alterations in malignant metastatic insulinomas. J Pathol 1995; 177:395-400.
33. Pavelic K, Hrascan R, Kapitanovic S, Vranes Z, Cabrijan T, Spaventi S et al. Molecular genetics of malignant insulinoma. Anticancer Res 1996; 16: 1707-1717.
34. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
35. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
36. Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A et al. BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 2013; 3: e126.
37. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DSMaitra A et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
38. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A 2013; 110:11988-11993.
39. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, Leung JY et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009; 69:7803-7810.
40. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011; 108: E699-E708.
41. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathwayindependent mechanisms. Nat Med 2011; 17: 1116-1120.
42. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-1657.
43. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-348.